Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) received a Hold rating from B.Riley FBR analyst Madhu Kumar today. The company’s shares closed yesterday at $44.66, close to its 52-week high of $45.61.
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 38.0% and a 58.3% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Clementia Pharmaceuticals Inc, Iovance Biotherapeutics Inc, and Allena Pharmaceuticals Inc.
Deciphera Pharmaceuticals Inc has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Based on Deciphera Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $21.43 million. In comparison, last year the company had a GAAP net loss of $7.71 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
